If 30% transitioned in such a manner, that would mean about 250-300 patients being added to the specialty side per month from the regular pile. The specialty was already 40% of total.
To others, you appear bitter. I think you could develop a palatable personality, as you seem to have some rudimentary sense of humor. Good luck.
Is it safe to anticipate that about 50% of NRx end up converting to specialty via DaVita and Fresnius for refills? I am trying to factor for the seeming lack of refills and the above average acceleration of specialty.
take a look at the trading and you will see 3 block trades between 10 and 10:30 this morning, each for over 100k shares, at prices below $6. I am pretty sure this was either a margin call or a fund selling out. Watch this thing close above $7 today or tomorrow.
Seems like more than the average daily volume was sold in the first hour. I get the feeling that this was due to a margin call. Does anyone have a better or different theory? Was there a downgrade?
Well, after the phase 3 trial for which the FDA approved ferric citrate for CKD 5 patients, the majority of patients taking the drug requested to continue taking it, despite the fact it was not yet approved. So, yes, they could not only tolerate it, but if fact generally prefer it.
You are contracts to you're, not your.
As in you're a moron, and your GED was bought, not earned.
Just putting that out there for all the illiterate.